TP53 mutations are potentially markers of poor prognosis for stage I lung adenocarcinoma patients. The mutation status of this gene may contribute to clinical decision-making with respect to selecting patients who may benefit from adjuvant therapy.
Keyphrases
- poor prognosis
- end stage renal disease
- genome wide
- long non coding rna
- decision making
- single cell
- newly diagnosed
- chronic kidney disease
- ejection fraction
- copy number
- peritoneal dialysis
- prognostic factors
- epidermal growth factor receptor
- electronic health record
- gene expression
- stem cells
- type diabetes
- squamous cell carcinoma
- skeletal muscle
- mesenchymal stem cells
- squamous cell
- bone marrow
- adipose tissue
- patient reported
- glycemic control